Serial No. 10/511,693 Docket No. 4439-4026

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- (currently amended) A remedy to be used in gene therapy of genetic <u>skin</u> diseases
 comprising an immunosuppressive agent and a gene correcting a deficient gene responsible for
 genetic <u>skin</u> diseases, wherein the gene correcting the deficient gene responsible for genetic <u>skin</u>
 diseases is used in a form of naked DNA or in a liposome subsumption form.
- (currently amended) The remedy to be used in gene therapy of genetic <u>skin</u> diseases
 according to claim 1, wherein the remedy consists of an immunosuppressive agent and a gene
 correcting the deficient gene responsible for genetic skin diseases.
- 3. (currently amended) The remedy to be used in gene therapy of genetic <u>skin</u> diseases according to claim 1 or 2, wherein the immunosuppressive agent has as an active ingredient an antagonist which inhibits the interaction between a CD40 receptor ligand, CD40L, and a CD40 receptor on the surface of antigen presenting cells, wherein the CD40L mediates a contact-dependent helper effector function on the surface of T cells.
- (currently amended) The remedy to be used in gene therapy of genetic <u>skin</u> diseases according to claim 3, wherein the antagonist inhibiting the interaction is an anti-CD40L antibody.
- (cancelled)
- (currently amended) The remedy to be used in gene therapy of genetic <u>skin</u> diseases according to claim 1 or 2, wherein the genetic skin disease is a recessive genetic skin disease.

 (currently amended) The remedy to be used in gene therapy of genetic <u>skin</u> diseases according to claim 6, wherein the recessive genetic <u>skin</u> disease is an autosomal recessive genetic <u>skin</u> disease.

- 8. (currently amended) A method for treating genetic skin diseases comprising administering a remedy comprising an immunosuppressive agent and a gene correcting the deficient gene responsible for genetic skin diseases according to claim 1 or 2.
- 9. (currently amended) The method for treating genetic <u>skin</u> diseases according to claim 8, wherein the genetic <u>skin</u> diseases include recessive genetic epidermolysis bullosa heredetaria dystrophica, <u>junctional epidermolysis</u> heredetaria <u>bullosa</u>, <u>hemidesmosome epidermolysis</u> bullosa hereditaria and ichthyosis congenita.

10-11. (cancelled)

- 12. (currently amended) The remedy to be used in gene therapy of genetic <u>skin</u> diseases according to claim 3, wherein the genetic skin disease is a recessive genetic skin disease.
- 13. (currently amended) The remedy to be used in gene therapy of genetic <u>skin</u> diseases according to claim 4, wherein the genetic <u>skin</u> disease is a recessive genetic <u>skin</u> disease.
- (cancelled)
- 15. (currently amended) The remedy to be used in gene therapy of genetic <u>skin</u> diseases according to claim 12, wherein the recessive genetic <u>skin</u> disease is an autosomal recessive genetic <u>skin</u> disease.
- 16. (currently amended) The remedy to be used in gene therapy of genetic <u>skin</u> diseases according to claim 13, wherein the recessive genetic <u>skin</u> disease is an autosomal recessive genetic <u>skin</u> disease.

Serial No. 10/511,693 Docket No. 4439-4026

17-25. (cancelled)

26. (currently amended) The method for treating genetic <u>skin</u> diseases according to claim 8, wherein the genetic <u>skin</u> disease is a recessive genetic <u>skin</u> disease.

27-33. (cancelled)

- 34. (currently amended) The method for treating genetic skin diseases according to claim
- 26, wherein the recessive genetic skin disease is an autosomal recessive genetic skin disease.

35-41. (cancelled)